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Development of Simplified Heterocyclic Acetogenin
Analogues as Potent and Selective Trypanosoma brucei
Inhibitors
Gordon J. Florence,* Andrew L. Fraser, Eoin R. Gould, Elizabeth F. King, Stefanie K. Menzies,
Joanne C. Morris, Marie I. Thomson, Lindsay B. Tulloch, Marija K. Zacharova, and
Terry K. Smith[a]
Neglected tropical diseases caused by parasitic infections are
an ongoing and increasing concern. They are a burden to
human and animal health, having the most devastating effect
on the world’s poorest countries. Building upon our previously
reported triazole analogues, in this study we describe the syn-
thesis and biological testing of other novel heterocyclic aceto-
genin-inspired derivatives, namely 3,5-isoxazoles, furoxans, and
furazans. Several of these compounds maintain low-micromo-
lar levels of inhibition against Trypanosoma brucei, whilst
having no observable inhibitory effect on mammalian cells,
leading to the possibility of novel lead compounds for selec-
tive treatment.
Neglected tropical diseases remain one of the largest concerns
in the developing countries of Africa and the South Americas,
both in terms of healthcare provision and financial impact on
the economies of the world’s poorest countries. This ongoing
threat has arisen from a lack of effective prevention methods
and minimal financial incentive to develop new therapeutic
agents.[1] One of these prevalent neglected tropical diseases
which has attracted attention in recent years is African sleep-
ing sickness or human African trypanosomiasis (HAT), caused
by the protozoan parasite Trypanosoma brucei. HAT is a serious
health concern in sub-Saharan Africa with >65 million people
at risk and with an annual mortality rate of approximately
9000 per annum.[2] The World Health Organization (WHO) esti-
mates 20000 new cases of HAT per year based on reported
cases, and has set an ambitious target to eradicate HAT by
2020.[3] Current drug treatments depend on the stage of HAT
and are difficult to administer to patients, requiring lengthy in-
fusion rates, and have varying degrees of human toxicity, while
showing low efficacy toward the parasite.[4] The combination
eflornithine/nifurtimox therapy (NECT) for stage 2 HAT has
proven successful, but resistance to this combination therapy
is emerging.[5] The lack of new effective therapeutic agents
and the onset of drug resistance highlights the urgent need
for the development of novel small molecule inhibitors of
T. brucei as potential lead compounds in the quest for new and
effective treatments for HAT.[6]
Acetogenins are a class of polyketide secondary metabolites
isolated from medicinal plants of the Annonaceae species, typi-
cally found in tropical regions of West Africa and South Ameri-
ca.[7, 8] Isolated in 2004 by Laurens et al. from the roots of bush
banana plant Uvaria chamae, chamuvarinin 1, displayed high
levels of cytotoxicity toward the KB3-1 cell line (IC50=0.8 nm).
[9]
In 2011, our research group reported the first total synthesis of
this unique tetrahydopyran-containing acetogenin and found
1 to exhibit unexpected trypanocidal activity in both the
bloodstream and procyclic forms of T. brucei (Figure 1).[10,11] In-
spired by chamuvarinin, we sought to design a series of simpli-
fied acetogenin-like analogues retaining key structural and ste-
reochemical features of the parent natural product. These sim-
plified analogues were assembled from a pool of readily acces-
sible chiral tetrahydropyran (THP) building blocks via copper-
mediated click chemistry.[12] These 1,4-triazole linked analogues,
including 2, maintained high trypanocidal activity with modest
selectivity profiles when compared against the human HeLa
cell line.
Following on from this success we sought to explore alter-
native heterocyclic linkers, in particular those that would di-
rectly attach the heterocycle spacer to the flanking THP rings,
in close analogy to the acetogenins. This direct linkage serves
to decrease the molecules’ available degrees of freedom and
so potentially improve binding efficiency. Moreover, we wished
to expand the toolbox of available reactions employing our
chiral THP building blocks as a source of molecular diversity.
This paper describes the expansion of our methodology to
new heterocycles: 3,5-isoxazoles, furoxans and furazans, as
well as their assessment as potential trypanocidal agents.
Despite their prevalence in natural products and their pres-
ence in several important drug compounds (e.g. , valdecoxib,
leflunomide, cloxacillin),[13] synthetic routes to aliphatic isoxa-
zoles remain extremely limited.[14] In particular, there are only
limited examples of a-oxygenated 3,5-isoxazoles and none of
these, to our knowledge, have been prepared in enantio-en-
riched form. Our approach employs the coupling of chiral a-
oxygenated alkynes with in situ prepared nitrile oxides, derived
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from the corresponding oximes, in a [3+2] cycloaddition.
Oximes 3–5 were rapidly accessed from the corresponding
THP alcohols by Swern oxidation and condensation with hy-
droxylamine (Scheme 1). Synthesis of the required
alkyne-substituted THP precursors 6–8 have been
previously described.[10,12]
A screen of isoxazole-forming reaction conditions,
focused on the choice of oxidising agent (required to
generate the nitrile oxide) found that tert-butylhypo-
chlorite was essential as the oxidising agent.[15, 16]
These conditions were successfully applied across
a range of substrates with varying side-chain substi-
tution and THP stereochemistry giving isoxazoles 9–
13 (Scheme 2). Yields were generally modest, but
nonetheless rapidly generated sufficient quantities of
these synthetically demanding substrates for biologi-
cal evaluation.
Screening results for our compounds against pro-
cyclic and bloodstream forms of T. brucei are outlined
in Table 1. Also included are the results of HeLa cell
line screening which we have employed as a repre-
sentative human cell line to assess our analogues’ selectivity. In
general, the isoxazole motif was well tolerated with compara-
ble activity toward T. brucei being maintained to the original
triazole analogues. The THP stereochemistry had a significant
influence on potency with the syn–syn compounds 9 and 10
and anti–anti 13 most potent. This is in contrast to our original
triazole series where anti–anti analogues were generally inac-
tive.[12] Of particular interest were the good levels of selectivity
displayed across
the series against T. brucei over mammalian HeLa cells, with all
but one of the analogues greater than 100 mm against HeLa
cells.
In the preparation of the isoxazole analogues, we identified
significant by-product formation- namely the furoxan arising
from nitrile oxide dimerisation.[17] These could be isolated in
trace amounts but were more productively generated by
simply warming the reaction after nitrile oxide formation inScheme 1. Synthesis of oximes 3–5 : a) (COCl)2, DMSO, CH2Cl2, Et3N, @78 8C!
RT; b) NH2OH·HCl, EtOH, 0 8C!RT.
Table 1. Biological data for isoxazoles 9–13.
Entry Analogue EC50 [mm] SI
[a]
T. brucei (BSF) T. brucei (insect) HeLa
1 9 4.5:0.2 19.6:3.1 107.8:4.9 24
2 10 9.0:0.6 43.8:4.0 >200 >22
3 11 30.9:1.4 69.3:5.1 >200 >6.5
4 12 17.4:0.5 >60 68.8:6.8 4.0
5 13 5.6:0.2 16.6:2.2 >100 >18
[a] Selectivity index: (EC50 HeLa)/(EC50 T. brucei).
Figure 1. Rationale of new T. brucei inhibitors inspired by acetogenins.
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order to induce dimerisation (in the absence of alkyne). This
generated furoxans 14–16 in useful quantities (Scheme 3).
While interesting in their own right, these compounds also al-
lowed rapid access to furazans 17–19 by simple reduction
with triethyl phosphite.
Screening of these compounds revealed that furoxans also
displayed encouraging T. brucei activity with anti–anti analogue
15 most potent and 5.6 times more selective over HeLa cells
(Table 2, entry 2).[18] Pleasingly, select furazan compounds main-
tain good T. brucei inhibition, while being essentially inactive
toward HeLa (18, >44-fold selectivity, entry 5). The selectivity
observed in this instance merits further detailed study of this
unusual heterocyclic framework.
We have demonstrated the utility of our chiral THP building
blocks by their elaboration to oximes and their use in ‘Click’ re-
actions with alkynes to generate complex isoxazole products.
Moreover, dimerisation of these oximes allows access to furo-
xan and furazan heterocycles. All series tested show encourag-
ing low micromolar activity in T. brucei and excellent selectivity
over mammalian cells in certain cases. These selectivities are
a significant improvement over our previously described tria-
zole compounds and can serve as a basis for further optimisa-
tion. Current efforts are focused on other heterocyclic spacers
as well as the synthesis of fluorescent and affinity tagged ver-
sions in order to isolate target protein(s) allowing us to estab-
lish the trypanocidal mode of action.
Scheme 2. Synthesis of isoxazoles 9–13 : a) tBuOCl then Et3N, @78 8C!RT.
Scheme 3. Synthesis of furoxans 14–16 and furazans 17–19 : a) tBuOCl then Et3N, @78 8C!RT; b) P(OEt)3, reflux.
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Table 2. Biological data for furoxans 14–16 and furazans 17–19.
Entry Analogue EC50 [mm] SI
[a]
T. brucei (BSF) T. brucei (insect) HeLa
1 14 8.7:0.4 >50 66.6:6.8 7.7
2 15 4.5:0.3 5.5:0.2 25.4:12.6 5.6
3 16 63.8:5.3 >500 >500 >7.8
4 17 16.3:0.5 26.6:1.9 142.9:17.3 8.8
5 18 11.3:0.6 >100 >500 >44
6 19 146:7.7 >500 >500 >3.4
[a] Selectivity index: (EC50 HeLa)/(EC50 T. brucei).
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